Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.
about
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipientsClinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin.Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experiencemTORC1 maintains renal tubular homeostasis and is essential in response to ischemic stress.Chronic allograft nephropathy score before sirolimus rescue predicts allograft function in renal transplant patients.Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.Late kidney allograft loss: what we know about it, and what we can do about itStrategies to prevent chronic allograft nephropathy in kidney transplantation: focus on calcineurin inhibitors.Current and future immunosuppressive strategies in renal transplantation.Clinical application of sirolimus in renal transplantation: an update.Sirolimus: a new option in transplantation.Liver transplantation for hepatitis C virus related liver diseaseCost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia.The role and value of sirolimus administration in kidney and liver transplantation.Antihypertensive agents and renal transplantation.Calcineurin inhibitor-free immunosuppression in kidney transplantation.Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result.Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation.Uric acid levels have no significant effect on renal function in adult renal transplant recipients: evidence from the symphony study.An evaluation of sirolimus in renal transplantation.mTOR controls kidney epithelia in health and disease.Systemic Immunomodulatory Strategies in High-risk Corneal Transplantation.Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase.Metabolism and homeostasis in the kidney: metabolic regulation through insulin signaling in the kidney.Olmesartan attenuates tacrolimus-induced biochemical and ultrastructural changes in rat kidney tissue.Randomized exposure-controlled trials; impact of randomization and analysis strategies.A Prospective Randomised Paired Trial of Sirolimus versus Tacrolimus as Primary Immunosuppression following Non-Heart Beating Donor Kidney Transplantation.Effects of sirolimus alone or in combination with cyclosporine A on renal ischemia/reperfusion injury.Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expression.Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation.Long-term outcomes following sirolimus conversion after renal transplantation.Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study.An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination.Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies.Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years.Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up.Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation.
P2860
Q24246340-36D27EE2-5A18-41A1-8826-9821EDC26E6EQ30419381-5EEB9D76-72F2-49A2-814F-0016D35A83ADQ33371289-FB5BFDC1-E9DE-42BA-903E-7EBBA1B72062Q33919585-2FD9AE8B-958C-4CA6-B89D-1079AD002FD8Q34236920-79F18309-D24C-4949-8CC8-588364484478Q35130521-2B245C1E-C603-44F1-BD21-933B8BFBBCEFQ35153318-2406329F-0A00-4CE2-944D-8F6C6E8278A2Q35841386-284440A0-117D-4B21-A34A-996B1251922AQ35906315-B4B4ED12-E517-44DC-8B2C-86E5C3DCA562Q36054093-D6BA6125-8061-41FE-A029-E04348D712E1Q36082082-22DFBA87-9A19-4F5A-B470-C3B6E91B6043Q36339458-C6D409EA-84E1-4E8E-AEEB-25DAC52B4532Q36536752-A242CA82-24D0-4229-86F3-15D33D536D1EQ36652031-D7E249B0-D725-422A-BBF6-1CF32A257211Q36765942-FF564C66-12FC-479C-A585-CF5E84987D7FQ36889001-AFD2F005-3DDF-4FCA-A1A3-4E9E3E2B461BQ37064446-66A3424A-43AF-468C-A92F-AED287BA42E5Q37097694-E49B15AF-725E-4B13-AB72-AF9268D440D8Q37184425-BCD9B63B-96E7-4D8D-B304-F4BE5C09DF92Q37378415-C64754E1-BF50-432E-A79B-FA192207BF34Q38038696-FCACAE49-1F1C-4C6B-8E5F-1EC9C3678568Q38185017-9B1BA6CF-0EB8-4B57-8237-FC39F50D81D1Q38904800-3BD16743-FB69-4AA3-A826-53B475F9FD4BQ39060681-74D60069-EBB9-4663-AFE3-4828956AD548Q39245624-F9092C89-8DC6-48C6-A9E3-5C6856F02805Q40736861-1719D59E-44DC-4BE6-968C-D1A112A8F3D6Q41121488-CE5A6795-C7B9-458A-9BBD-DC32C693C8A7Q41661712-1F6C5375-ABEF-43A7-BBFC-6B7F4F76CCA3Q43022805-D9259145-CD52-44FC-8B46-653E2022A073Q43298132-E7427E62-EAA9-4905-B8ED-C34DB030AFB6Q43984395-B92046D4-00A6-425C-AEF2-9B0BD21BA5E3Q43995286-0CDEFC80-4DC7-4EA8-843B-2B32F3D25597Q44402537-EEAF1B43-197B-4010-899B-66808D8A978CQ44544352-E0A62A10-B282-4FA8-9F77-C2B3491548A2Q44554143-26208F04-90A1-48E9-AB10-62143EABF955Q44845684-B8DB78E0-3E28-4646-8974-C80FD789A30DQ44854978-BA8BE96D-8CB7-48E1-A680-0AA99E37D566Q44899016-C1D0A4C7-AEFC-4865-8A38-FA5FEFEA11DCQ44935467-A188E61C-34A4-432D-B7BF-690785D15334Q44989307-5E396664-E5C4-40E8-BB4B-CC692EB4FC4E
P2860
Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Sirolimus does not exhibit nep ...... n renal transplant recipients.
@en
Sirolimus does not exhibit nep ...... n renal transplant recipients.
@nl
type
label
Sirolimus does not exhibit nep ...... n renal transplant recipients.
@en
Sirolimus does not exhibit nep ...... n renal transplant recipients.
@nl
prefLabel
Sirolimus does not exhibit nep ...... n renal transplant recipients.
@en
Sirolimus does not exhibit nep ...... n renal transplant recipients.
@nl
P2093
P2860
P1476
Sirolimus does not exhibit nep ...... in renal transplant recipients
@en
P2093
Amado Andres
Carl G Groth
Dominique Durand
Eric Nègre
Henri Kreis
James T Burke
Josep M Campistol
José M Morales
Lars Wramner
Sirolimus European Renal Transplant Study Group
P2860
P304
P356
10.1034/J.1600-6143.2002.20507.X
P407
P577
2002-05-01T00:00:00Z